CAS: 1646839-59-9; N-(5-((6,7-Dimethoxyquinolin-4-yl)Oxy)Pyridin-2-yl)-2,5-Dioxo-1-Phenyl-1,2,5,6,7,8-Hexahydroquinoline-3-Carboxamide
- 英文名称N-(5-((6,7-Dimethoxyquinolin-4-yl)Oxy)Pyridin-2-yl)-2,5-Dioxo-1-Phenyl-1,2,5,6,7,8-Hexahydroquinoline-3-Carboxamide
- 中文名称N-[5-[(6,7-二甲氧基-4-喹啉基)氧基]-2-吡啶基]-1,2,5,6,7,8-六羟基-2,5-二氧代-1-苯基-3-喹啉甲酰胺
- IUPAC名称N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide
- 其它别名Tamnorzatinib; 0Vcb95Rhrv; N-(5-((6,7-Dimethoxyquinolin-4-yl)Oxy)Pyridin-2-yl)-2,5-Dioxo-1-Phenyl-1,2,5,6,7,8-Hexahydroquinoline-3-Carboxamide; N-[5-(6,7-Dimethoxyquinolin-4-yl)Oxypyridin-2-Yl]-2,5-Dioxo-1-Phenyl-7,8-Dihydro-6H-
- CAS编号1646839-59-9
- MFCD编号:MFCD32689448
- FDA UNII编号:0VCB95RHRV
- 分子式:C32H26N4O6分子量:562.58
- 产品CID: 836820
- 产品分类有机原料 → 有机杂环化合物 → 喹啉及其衍生物
物理性质
- 沸点804.0±65.0 °C(预测)
- 密度1.43±0.1 g/cm3(预测)
- pKa:8.50±0.20(预测)
- LogP:3.8
- 溶解性DMF: 30 mg/mL,DMSO: 30 mg/mL,DMSO:Pbs (Ph 7.2) (1:1): 0.5 mg/mL
- 外观形态淡黄色至黄色结晶性固体
- 储存条件储存在 -20°C
- 产品应用该化合物是AXL和MER TYROSINE 直流体系的强大,选择性和口服活性抑制剂,IC50值分别为0.7 NM和1.0 NM,克服了EGFR-TKI(如OSIMERTINIB或DACOMITINIB)在EGRFR非小型细胞肺癌细胞细胞(NSCLC)中过度表达的AXL(NSCCLC). 此外,ONO-7475抑制了急性类流质白血病细胞(AML)的扩散,并诱发细胞死亡,这些细胞在FMS类类似暴风菌的3 (FLT3-ITD)中同时存在突变.
上下游产品
2,5-二氧代-1-苯基-1,2,5,6,7,8-六氢-3-喹啉羧酸 2,5-Dioxo-1-Phenyl-1,2,5,6,7,8-Hexahydro-3-Quinoline Carboxylic Acid 125885-51-0合成工艺路线路线简述
📜2-氯-5-羟基吡啶置于tris(Dibenzylideneacetone)Dipalladium(0) Chloroform Complex,三乙胺,N,N-二异丙基乙胺,Methanaminium,N-[(Dimethylamino)(3H-1,2,3-Triazolo[4,5-B]Pyridin-3-Yloxy)Methylene]-N-Methyl-,Hexafluorophosphate(1-),Lithium Hexamethyldisilazane体系中,用 四氢呋喃,N,N-二甲基甲酰胺,氯苯 用作溶剂,化学反应 157.5H,反应生成N-[5-[(6,7-二甲氧基-4-喹啉基)氧基]-2-吡啶基]-1,2,5,6,7,8-六羟基-2,5-二氧代-1-苯基-3-喹啉甲酰胺
参考文献:Ethane-Sulfonate Salt Of Quinoline Derivative
标题:Ethane-Sulfonate Salt Of Quinoline Derivative
摘要:本发明涉及一种n-{5-[(6,7-二甲氧基-4-喹啉基)氧基]-2-吡啶基}-2,5-二氧杂-1-苯基-1,2,5,6,7,8-六氢-3-喹啉羧酰胺的乙烷磺酸盐,其具有axl抑制活性,并可用作预防和/或治疗免疫性疾病,癌症等的药物,以及其晶体和制药组合物.
海关参考信息
- 2905110000-甲醇
2907210001-间苯二酚
2912110000-甲醛
2912120000-乙醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Lung Cancer. Clin Cancer Res. 2020 Jan 17. doi: 10.1158/1078-0432.CCR-19-2321. Epub ahead of print. 102(12):2048-2057. doi: 10.3324/haematol.2017.168856. Epub 2017 Sep 14.
合成参考文献
参考文献:10.3324/haematol.2021.278369
摘要:Post SM, Ma H, Malaney P, Zhang X, Aitken MJL, Mak PY, Ruvolo VR, Yasuhiro T, Kozaki R, Chan LE, Ostermann LB, Konopleva M, Carter BZ, DiNardo C, Andreeff MD, Khoury JD, Ruvolo PP. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. haematol. 2021 Nov 04;107(6):1311–22. doi: 10.3324/haematol.2021.278369.
📝 需求与反馈
尽可能描述清楚需求与问题信息
